metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
metastatic, hormone-sensitive prostate cancer metastatic, hormone-sensitive prostate cancer
versus androgen deprivation therapy (ADT)
	abiraterone plus ADT
	LATITUDE, 2019 Lancet Oncol 2019; 20:686-700 NEJM NCT01715285	RCT	metastatic, hormone-sensitive prostate cancer	androgen-deprivation therapy plus abiraterone acetate (1000 mg daily, given once daily as four 250-mg tablets) plus prednisone (5 mg daily)	androgen-deprivation therapy plus dual placebos	patients with newly diagnosed, metastatic, castration-sensitive prostate cancer	-/-	NA	conclusif	demonstrated 38 % decrease in deaths (OS),deaths (OS) (PE)
	STAMPEDE abiraterone, 2017 NEJM NCT00268476	RCT	metastatic, hormone-sensitive prostate cancer	abiraterone acetate (1000 mg daily) and prednisolone (5 mg daily)	ADT alone	Prostate Cancer Not Previously Treated with Hormone Therapy	-/-	NA	conclusif	demonstrated 37 % decrease in deaths (OS) (PE)
	apalutamide plus ADT
	TITAN, 2019 N Engl J Med 2019 Jul 4;381(1):13-24. NCT02489318	RCT	metastatic, hormone-sensitive prostate cancer				525 / 527	NA	conclusif	demonstrated 33 % decrease in deaths (OS) (PE)
	docetaxel plus ADT
	NCI E3805 (Scott), 2017 Urol Oncol 2017; 35:123 NEJM NCT00309985	RCT	metastatic, hormone-sensitive prostate cancer				397 / 393	NA	conclusif	demonstrated 39 % decrease in deaths (OS),deaths (OS) (PE)
	STAMPEDE docetaxel, 2016 Lancet 2016 Mar 19;387(10024):1163-77. NCT00268476		metastatic, hormone-sensitive prostate cancer				-/-	NA	suggested	suggested 22 % decrease in deaths (OS)
	GETUG-AFU 15, 2013 Lancet Oncol 2013 Feb;14(2):149-58. NCT00104715	RCT	metastatic, hormone-sensitive prostate cancer	docetaxel and androgen-deprivation therapy (ADT)	androgen-deprivation therapy (ADT) alone	patients with metastatic non-castrate prostate cancer	-/-	NA	inconclusive	no statistically significant result
	CHAARTED unpublished Journal of Clinical Oncology NCT00268476		metastatic, hormone-sensitive prostate cancer				-/-	NA	suggested	suggested 28 % decrease in deaths (OS)
	enzalutamide plus ADT
	ARCHES, 2022 Journal of Clinical Oncology Journal of Clinical Oncology NCT02677896	RCT	metastatic, hormone-sensitive prostate cancer				574 / 576	NA	suggested	suggested 34 % decrease in deaths (OS)
	ENZAMET, 2019 N Engl J Med 2019; 381:121-131 NCT02446405	RCT	metastatic, hormone-sensitive prostate cancer	enzalutamide plus testosterone suppression	standard nonsteroidal antiandrogen therapy	men with metastatic, hormone-sensitive prostate cancer	-/-	NA	suggested	suggested 33 % decrease in deaths (OS),deaths (OS)
versus docetaxel plus ADT
	abiraterone plus docetaxel plus ADT
	PEACE-1, 2022 The Lancet NCT01957436	RCT	metastatic, hormone-sensitive prostate cancer	abiraterone androgen deprivation therapy with docetaxel population	androgen deprivation therapy with docetaxel population	de novo metastatic castration-sensitive prostate cancer	355 / 355	NA	conclusif	demonstrated 25 % decrease in deaths (OS) (PE)
	darolutamide plus doxetaxel plus ADT
	ARASENS , 2022 New England Journal of Medicine NCT02799602	RCT	metastatic, hormone-sensitive prostate cancer	darolutamide, androgen-deprivation therapy, and docetaxel	androgen-deprivation therapy, and docetaxel	metastatic, hormone-sensitive prostate cancer,	651 / 655	NA	conclusif	demonstrated 32 % decrease in deaths (OS) (PE)

metastatic, hormone-sensitive prostate cancer metastatic, hormone-sensitive prostate cancer